AdAlta Announces Positive Pre-clinical Data Showing Lead Drug Candidate Has Broad Fibrosis Treatment Potential Read More
AdAlta licenses Alzheimer’s disease-specific shark antibodies to Crossbeta Biosciences for therapeutic and diagnostic development Read More
AdAlta and XL-protein announce collaboration to develop a long acting version of its lead fibrosis drug candidate AD-114 using PASylation Technology Read More
AdAlta signs agreement with FujiFilm Diosynth Biotechnologies to begin manufacturing its lead fibrosis drug candidate Read More
AdAlta Receives Australian Government Grant to Advance Understanding of Potential New Lung Fibrosis Therapy Read More
Drug Discovery Company AdAlta Raises AU$10m in Over-Subscribed Australian IPO to Accelerate New Therapies for Lung Fibrosis Read More
Australian Drug Discovery Company AdAlta, Announces IPO to Accelerate New Therapies for Lung Fibrosis Read More